SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76913.50
582.86 (-0.75%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
121	Jubilant Pharmova Ltd.	Q V+ PT	14,761 Small Cap	926.75 (0.01%)	N/A	6.56	-24.99	-38.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Suraksha Diagnostic Ltd.	Q V PT	1,476 Small Cap	283.45 (0.50%)	44.12	6.18	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Solara Active Pharma Sciences Ltd.	Q V PT	2,402 Small Cap	498.60 (1.85%)	N/A	1.9	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	Indoco Remedies Ltd.	Q V+ PT	1,937 Small Cap	209.90 (0.33%)	N/A	1.8	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Health X Platform Ltd.	Q V PT	884 Small Cap	277.85 (-1.31%)	N/A	3.3	109.13	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
126	Nectar Lifesciences Ltd.	Q V+ PT	241 Small Cap	12.40 (-1.43%)	N/A	0.35	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
RPG Life Sciences	2,297.45	13.59%
Syngene Internation.	467.90	8.30%
Guj. Kidney & Super	125.40	5.38%
Kopran	164.70	5.14%
Aarti Pharmalabs	744.25	4.91%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
3B Blackbio Dx	1,206.60	-4.77%
Lincoln Pharma	645.40	-4.19%
Sun Pharma Adv. Res	142.85	-3.71%
Laxmi Denta	199	-3.40%
Guj. Themis Biosyn	363.75	-3.22%

News about Top Pharma Companies in India

Apr, 2026

USFDA issues EIR with VAI classification to Solara Active Pharma Sciences’ Puducherry facility

The unannounced inspection was carried out by the US Food and Drug Administration between February 02, 2026 to February 6, 2026

Apr, 2026

Jubilant Pharmova informs about board meeting

Jubilant Pharmova has informed that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026, inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026. and Recommendation of Final Dividend, if any, for the Financial Year ended March 31, 2026.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Sastasundar Ventures informs about updates

Sastasundar Ventures has informed that Company have received query from Exchanges to furnish bifurcation of revenue in the CA certificate, affirming the compliance with the conditions prescribed in Regulation 45 of the SEBI (LODR) Regulations, 2015. Thereafter, the Company has shared the revised CA certificate with the Exchanges and the same is attached for the purpose of information to investors. The Certificate was attached to the Postal Ballot Notice dated January 7, 2026 which was sent to Stock Exchange and dispatched to the shareholders on January 13, 2026. The Company shall send the Revised CA certificate to the shareholders, at the next available opportunity either in the Notice of General Meeting or such other mode as specified in Companies Act, 2013 read with SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Nectar Lifesciences informs about compliance report

Pursuant to the Regulation 24A of Securities and Exchange of Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 and as amended upto date, Nectar Lifesciences has informed that it attached the Annual Secretarial Compliance Report for the year ended on March 31, 2026, duly signed by Company Secretary in practice.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

USFDA concludes inspection of Indoco Remedies’ testing facility with zero observation

The inspection was carried out from April 08, 2026 to April 10, 2026

Mar, 2026

Solara Active Pharma Sciences informs about outcome of rights issue committee meeting

Solara Active Pharma Sciences has informed that the Meeting of the Rights Issue Committee of the Board of Directors of the Company held today, Tuesday, March 24, 2026 has considered and approved the making of Second & Final call of ? 112.50/- per equity shares (? 3.00/- towards face value and ? 109.50/- towards securities premium) per Rights Share in respect of partly-paid Rights Shares, on Rights basis, pursuant to the Letter of Offer dated May 09, 2024. Rights Issue Committee has fixed Thursday, April 02, 2026, as the Record date for the purpose of determining the holders of partly paid-up Equity Shares to whom the call notice will be dispatched for payment of the call. Details under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 has been enclosed as Annexure I. The Rights Issue Committee Meeting commenced at 9.30 am and concluded at 9.55 am.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Yatharth Hospital & Trauma Care Services Ltd.	7,894 Crore
2	3B Blackbio Dx Ltd.	1,036 Crore
3	Neuland Laboratories Ltd.	19,243 Crore
4	Vimta Labs Ltd.	2,043 Crore
5	Max Healthcare Institute Ltd.	96,657 Crore
6	Novartis India Ltd.	2,550 Crore
7	Narayana Hrudayalaya Ltd.	36,093 Crore
8	Anthem Biosciences Ltd.	42,676 Crore
9	Jagsonpal Pharmaceuticals Ltd.	1,412 Crore
10	Kwality Pharmaceuticals Ltd.	1,641 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,431	54,039	35.46	12.32	24.79	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,192	1,41,859	62.44	15.62	35.30	26.68
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	24.45
Lupin Ltd. (M)	Somewhat Good	2,304	1,05,320	22.67	5.06	13.52	20.83
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
No Yearly Gainers for this list.				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	17.81
Mankind Pharma Ltd. (M)	Very Good	2,247	92,744	54.44	5.81	32.80	14.65
Laurus Labs Ltd. (M)	Very Good	1,099	59,336	66.76	11.20	33.62	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	13.26
Ajanta Pharma Ltd. (S)	Very Good	2,825	35,289	34.78	7.69	23.80	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	892	89,721	18.17	3.42	11.35	30.57
Cipla Ltd. (L)	Very Good	1,310	1,05,811	23.27	3.15	14.04	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,808	4,33,848	39.75	5.34	21.73	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,323	1,10,421	19.83	2.97	11.91	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,048	32,884	45.21	8.43	28.55	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

USFDA issues EIR with VAI classification to Solara Active Pharma Sciences’ Puducherry facility

Jubilant Pharmova informs about board meeting

Sastasundar Ventures informs about updates

Nectar Lifesciences informs about compliance report

USFDA concludes inspection of Indoco Remedies’ testing facility with zero observation

Solara Active Pharma Sciences informs about outcome of rights issue committee meeting

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.